Latest Quinazolines Stories
Data Include First Presentation of Phase III Progression Free Survival Results for Pazopanib in Kidney Cancer LONDON and PHILADELPHIA, May 11 /PRNewswire/ -- GlaxoSmithKline (GSK) Oncology announced that new clinical data from nine of its oncology molecules will be featured in various presentations at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando beginning May 29.
Current and Emerging Targeted Therapies Such As AstraZeneca's Iressa and Roche's Avastin Will Drive the Market From 2008 to 2013, According to a New Report from Decision Resources WALTHAM, Mass., May 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in China will more than double by 2013, growing from $307 million in 2008 to $648 million in 2013.
Test will help oncologists guide treatment of patients with non-small cell lung cancer BROOMFIELD, Colo., May 5 /PRNewswire/ -- Biodesix, Inc. today announces U.S.
An oral medication could help some patients with inflammatory breast cancer.
Finally some promising news about pancreatic cancer, one of the most fatal cancers, due to the difficulties of early detection and the lack of effective therapies
LONDON and PHILADELPHIA, April 1, /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced the submission of two simultaneous regulatory applications to expand the use of TYVERB(R)/TYKERB(R) (lapatinib).
A breast cancer chemotherapy drug shows benefits in fighting one type of breast cancer but not another type, U.S. researchers say.
A recent study suggests that advanced lung cancer patients might be able to avoid another chemotherapy treatment by taking a targeted pill treatment.
Genentech, a biotechnology company, and OSI Pharmaceuticals, have announced that a global Phase III study has met its primary endpoint and showed that Tarceva significantly extended the time patients with advanced non-small cell lung cancer lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo.
Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.